메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively. - Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 injection is expected in the second quarter of 2026. HONG KONG, Jan. 20, 2026 -- Ascletis Pharma Inc. (HK
- 김갑성 기자
- 2026-01-20 17:00
Merck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation

[ 메디채널 김갑성 기자 ] Strategic collaboration establishes a framework to integrate automated experimentation and advanced chemistry workflows to accelerate research and discovery in Life Science and Electronics SINGAPORE and SHANGHAI, Jan. 20, 2026 -- Merck, a leading science and technology company, and ChemLex, a Singapore-headquartered innovation company pioneering AI-driven automated chemical synthesis, today announced the signing of a Memorandum of Understanding (MOU) to explore a strategic collaboration in evolving R&D paradigms. The MOU reflects a shared commitment to adv
- 김갑성 기자
- 2026-01-20 16:17
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

DAEJEON, South Korea, Jan. 20, 2026 -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ technology, for the development and commercialization of a subcutaneous formulation of dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody. Alteogen will receive an upfront payment of US$20 million and is eligible to receive milestone payments up
- 김갑성 기자
- 2026-01-20 15:55
Infinitus Recognised as a Top Employer in China for 2026 for the Sixth Consecutive Year

GUANGZHOU, China, Jan. 20, 2026 -- Infinitus, a leader in the health and wellness industry, is pleased to announce that it has been recognised as a "Top Employer in China for 2026" by the Top Employers Institute, marking the sixth consecutive year the company has earned this distinguished honour. The Certification follows the Institute's rigorous annual HR Best Practices Survey and independent validation process and was announced on January 15, 2026. At Infinitus, people are at the heart of the organisation's long-term development — the foundation of its business and
- 김갑성 기자
- 2026-01-20 15:51
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion[1]), in line with upgraded guidance of US$800-$820 million[2] (previously US$770-800 million). Q4 2025 unaudited Group revenue of approximately US$208 million, up 46% year-over-year. Precision Me
- 김갑성 기자
- 2026-01-20 15:16
cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments

SYDNEY, Jan. 20, 2026 -- Cerebral Palsy Alliance, The University of Sydney, and CSIRO, Australia's national science agency, have commissioned Miroma Project Factory to deliver a groundbreaking mobile app that helps people with cerebral palsy (CP), their carers, and clinicians understand and navigate evidence-based treatments with confidence. Developed as part of the national TRANSMIT project (Translation Strategy Improving Function), cpThrive transforms decades of research into an easy-to-use "traffic light" guide, helping people with lived experience of CP to quickly
- 김갑성 기자
- 2026-01-20 13:46
Beauty Farm Issues Positive Profit Alert for 2025

HONG KONG, Jan. 20, 2026 -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or the "Company") (02373.HK), one of the largest beauty and wellness services providers in China, issued a positive profit alert for the year ended December 31, 2025. As disclosed, the Company anticipates revenue of not less than RMB 3.0 billion for the year ended December 31, 2025, representing robust growth of not less than 16% compared with the corresponding period in 2024. Based on a preliminary assessment of the unaudited results, Beauty Farm expects an adjusted net profit o
- 노기식 기자
- 2026-01-20 12:14
Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women's and Children's Healthcare in India

SINGAPORE, Jan. 20, 2026 -- Novo Holdings, a leading global healthcare and life sciences investor, today announced that it has made an investment in Surya Hospitals, the largest private women's and children's specialty hospital chain in Western India. The investment is for a significant minority stake and underscores Novo Holdings' continued commitment to building scaled, high-quality healthcare platforms in India. Founded in 1984, Surya Hospitals has a legacy of over four decades and is widely recognised as a centre of excellence for women's, neonatal, and paediatric care. The Group o
- 황정호 기자
- 2026-01-20 09:00
AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities

HONG KONG, Jan. 20, 2026 -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has recently received clinical trial approval from the National Medical Products Administration. This marks a further enrichment and enhancement of AIM's research and development pipeline in the pneumococcal vaccine field. Pneumococcal diseases are among the diseases designated as "extremely high priority" for vaccination prevention by the World Healt
- 김갑성 기자
- 2026-01-20 08:23
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), Telix's lead prostate cancer imaging agent. The NDA was submitted with Telix's strategic partner for the Greater China region, Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma). Seeking a b
- 김갑성 기자
- 2026-01-20 06:15

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-03-03_TUE

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 03시 40분